168 related articles for article (PubMed ID: 37341812)
21. Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
Wang X; He J; Li J; Wu C; Yue M; Niu S; Jia Y; Jia Z; Cai L; Liu Y
J Cancer Res Clin Oncol; 2024 Jan; 150(2):43. PubMed ID: 38280970
[TBL] [Abstract][Full Text] [Related]
22. Squamous intraepithelial lesions of the cervix, invasive cervical carcinoma, and immunosuppression induced by human immunodeficiency virus in Africa. Dyscer-CI Group.
La Ruche G; Ramon R; Mensah-Ado I; Bergeron C; Diomandé M; Sylla-Koko F; Ehouman A; Touré-Coulibaly K; Welffens-Ekra C; Dabis F
Cancer; 1998 Jun; 82(12):2401-8. PubMed ID: 9635533
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of immune checkpoint inhibitors according to PD-L1 tumor proportion scores in non-small cell lung cancer.
Park S; Choi YD; Kim J; Kho BG; Park CK; Oh IJ; Kim YC
Thorac Cancer; 2020 Feb; 11(2):408-414. PubMed ID: 31841269
[TBL] [Abstract][Full Text] [Related]
24. The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer.
Gordetsky JB; Montgomery KW; Giannico GA; Rais-Bahrami S; Thapa P; Boorjian S; Frank I; Cheville J
Int J Surg Pathol; 2022 Feb; 30(1):6-14. PubMed ID: 34180731
[No Abstract] [Full Text] [Related]
25. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
[TBL] [Abstract][Full Text] [Related]
26. The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix.
Karpathiou G; Chauleur C; Mobarki M; Peoc'h M
Pathol Res Pract; 2020 Jan; 216(1):152782. PubMed ID: 31862202
[TBL] [Abstract][Full Text] [Related]
27. Real-world prevalence of PD-L1 expression in non-small cell lung cancer: an Australia-wide multi-centre retrospective observational study.
Russell PA; Farrall AL; Prabhakaran S; Asadi K; Barrett W; Cooper C; Cooper W; Cotton S; Duhig E; Egan M; Fox S; Godbolt D; Gupta S; Hassan A; Leslie C; Leong T; Moffat D; Qiu MR; Sivasubramaniam V; Skerman J; Snell C; Walsh M; Whale K; Klebe S
Pathology; 2023 Dec; 55(7):922-928. PubMed ID: 37833206
[TBL] [Abstract][Full Text] [Related]
28. Laminin-5 gamma 2 chain expression in cervical intraepithelial neoplasia and invasive cervical carcinoma.
Noel JC; Fernandez-Aguilar S; Fayt I; Buxant F; Ansion MH; Simon P; Anaf V
Acta Obstet Gynecol Scand; 2005 Nov; 84(11):1119-23. PubMed ID: 16232183
[TBL] [Abstract][Full Text] [Related]
29. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma.
Downes MR; Slodkowska E; Katabi N; Jungbluth AA; Xu B
Histopathology; 2020 Jan; 76(2):191-200. PubMed ID: 31243779
[TBL] [Abstract][Full Text] [Related]
30. PD-L1 expression in pancreatic adenosquamous carcinoma: PD-L1 expression is limited to the squamous component.
Tanigawa M; Naito Y; Akiba J; Kawahara A; Okabe Y; Ishida Y; Ishikawa H; Hisaka T; Fujita F; Yasunaga M; Shigaki T; Sudo T; Mihara Y; Nakayama M; Kondo R; Kusano H; Shimamatsu K; Okuda K; Akagi Y; Yano H
Pathol Res Pract; 2018 Dec; 214(12):2069-2074. PubMed ID: 30477643
[TBL] [Abstract][Full Text] [Related]
31. The expression of p16 and galectin-3 in cervical intraepithelial neoplasia (CIN) and squamous cell carcinoma (SCC) uterine cervix.
Kumar R; Mandal S; Arora P; Mala YM; Khurana N
J Obstet Gynaecol; 2021 Jul; 41(5):785-790. PubMed ID: 33073644
[TBL] [Abstract][Full Text] [Related]
32. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
[TBL] [Abstract][Full Text] [Related]
33. Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
Venancio PA; Consolaro MEL; Derchain SF; Boccardo E; Villa LL; Maria-Engler SS; Campa A; Discacciati MG
Cancer Cytopathol; 2019 Sep; 127(9):586-597. PubMed ID: 31412167
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
[TBL] [Abstract][Full Text] [Related]
35. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix.
Heeren AM; Punt S; Bleeker MC; Gaarenstroom KN; van der Velden J; Kenter GG; de Gruijl TD; Jordanova ES
Mod Pathol; 2016 Jul; 29(7):753-63. PubMed ID: 27056074
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
Yang W; Song Y; Lu YL; Sun JZ; Wang HW
Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
[TBL] [Abstract][Full Text] [Related]
37. Interobserver Agreement on the Interpretation of Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Among Gynecologic Pathologists.
Mills AM; Bennett JA; Banet N; Watkins JC; Kundu D; Pinto A
Am J Surg Pathol; 2023 Aug; 47(8):889-896. PubMed ID: 37272261
[TBL] [Abstract][Full Text] [Related]
38. The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer.
Yu SL; Hsiao YJ; Cooper WA; Choi YL; Avilés-Salas A; Chou TY; Coudry R; Raskin GA; Fox SB; Huang CC; Jeon YK; Ko YH; Ku WH; Kwon GY; Leslie C; Lin MC; Lou PJ; Scapulatempo-Neto C; Mendoza Ramírez S; Savelov N; Shim HS; Lara Torres CO; Cunha IW; Zavalishina L; Chen YM
Pathology; 2023 Feb; 55(1):19-30. PubMed ID: 36319485
[TBL] [Abstract][Full Text] [Related]
39. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
40. Human papillomavirus infection and cervical cancer in Brazil: a retrospective study.
Cavalcanti SM; Deus FC; Zardo LG; Frugulhetti IC; Oliveira LH
Mem Inst Oswaldo Cruz; 1996; 91(4):433-40. PubMed ID: 9070405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
